The nontuberculous mycobacteria (NTM) market across the seven major markets (7MM: the USA, France, Germany, Italy, Span, the UK and Japan) is forecast to grow at a compound annual growth rate (CAGR) of 8.8% from $2.0 billion in 2023 to $4.6 billion in 2033.
Pharma data and analytics company GlobalData’s latest report, “Nontuberculous Mycobacteria (NTM): Opportunity Assessment and Forecast”, reveals that market growth will primarily be driven by the launch of several novel pipeline agents, as well as the projected increase in the number of diagnosed prevalent cases of NTM.
Stephanie Kurdach, infectious disease analyst at GlobalData, commented: “The NTM market is currently dominated by off-label usage of highly genericized, broad-spectrum antibiotics. There are several novel late-stage pipeline products in development specifically for the treatment of NTM infections.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze